Explore the detailed record of transactions filed by 黄奕波, Director. Director active across 1 companies, notably 开立医疗. Aggregated, 36 filings have been published. Regulator: AMF. The full history is openly available.
Declarations 36 total
20,000 shares
SSE:273000000597979940 · 8 May 2026
10,000 shares
SSE:273000000229705500 · 3 Mar 2026
13,000 shares
SSE:273000000229705630 · 3 Mar 2026
20,600 shares
SSE:273000000229705600 · 2 Mar 2026
3,000 shares
SSE:273000000229705400 · 2 Mar 2026
Executives ● Sale聚 聚和材料 23 SSE 101,600 shares
SSE:273000000371938050 · 2 Mar 2026
8,000 shares
SSE:273000000229705340 · 2 Mar 2026
200 shares
SSE:273000000229711840 · 19 Jan 2026
5,000 shares
SSE:173000009663804770 · 23 Oct 2025
Executives ● Purchase聚 聚和材料 8 SSE 746 shares
SSE:173000007168902080 · 13 Dec 2023
Ideal exit: 8 Sept 2024 (T+270) 250,000 shares
SSE:173000007143192580 · 1 Dec 2023
Executives ● Purchase成 成大生物 11 SSE 5,000 shares
SSE:173000006468970340 · 11 Apr 2023
Ideal exit: 6 Jan 2024 (T+270) Executives ● Purchase成 成大生物 7 SSE 13,200 shares
SSE:173000006468970300 · 11 Apr 2023
Ideal exit: 6 Jan 2024 (T+270) Executives ● Purchase神 神火股份 7 SZSE 2,200 shares
SZSE:173000006441830900 · 31 Mar 2023
Ideal exit: 26 Dec 2023 (T+270) 346,700 shares
SSE:173000006419731740 · 29 Mar 2023
30,800 shares
SSE:173000006402427900 · 27 Mar 2023
427,100 shares
SSE:173000006396974820 · 24 Mar 2023
Executives ● Sale开 开立医疗 7 SZSE 200,000 shares
SZSE:173000005934830620 · 30 Sept 2022
Executives ● Purchase南 南微医学 2 SSE 2,052 shares
SSE:173000005804796800 · 23 Aug 2022
Ideal exit: 20 May 2023 (T+270) 2,380,000 shares
SSE:173000005730496420 · 28 Jul 2022
150,000 shares
SSE:173000005605513150 · 16 Jun 2022
Executives ● Purchase南 南微医学 11 SSE 8,400 shares
SSE:173000005457335900 · 22 Dec 2021
Ideal exit: 18 Sept 2022 (T+270) Executives ● Purchase南 南微医学 7 SSE 12,600 shares
SSE:173000005457335940 · 22 Dec 2021
Ideal exit: 18 Sept 2022 (T+270) 134,500 shares
SSE:173000005188422140 · 22 Dec 2021
Executives ● Purchase南 南微医学 11 SSE 6,750 shares
SSE:173000005457335970 · 22 Dec 2021
Ideal exit: 18 Sept 2022 (T+270) 25 of 36 declarations
Load more (11 remaining) About 黄奕波 Huang Yibo is a director and executive at Kaili Medical. He is responsible for corporate strategy and operational management, contributing to innovation and growth in the medical sector.